Dr. Cora Sternberg on Imaging and Treatment Changes for nmCRPC

Cora N. Sternberg, MD, Medical Oncologist at Weill Cornell Medicine and New York-Presbyterian Hospital, shares the therapeutic options for patients with nmCRPC, how stage at diagnosis impacts treatment options, and how PSMA-PET imaging in future clinical trials figures to impact disease staging and treatment decision-making.

Dr. Sternberg details the three clinical trials most influential in the treatment of patients with nmCRPC today: PROSPER, SPARTAN, and ARAMIS.

She explains how until now, nmCRPC has been defined by CT scans and bone scans. Clinical trials have yet to fully investigate PSMA-PET scans, which was just recently approved by the FDA in the United States.

View Dr. Sternberg’s other comments on Mutation Status as a Treatment Driver in Advanced Prostate Cancer.